In particular, Secukinumab, a fully humanized anti-IL17A mAb aimed at suppressing pathogenic Th17 and Th1-like Th17 cell subset, has been approved in 2005 as first-line therapy for psoriasis [211,212]. The gene discussed is IL17A; the disease is psoriasis.